Streetbeat News

Stock Prices

TG

Tredegar reported a significant decrease in Q1 earnings and sales YoY, with a loss of $(0.16) per share compared to a gain of $0.07 per share last year, and sales dropping to $114.22M from $191.12M.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 12:03 pm

MPW

Medical Properties Trust (MPW) reported Q1 2024 FFO of $0.24 per share, missing the $0.27 estimate, and sales of $271.316M, below the $276.455M estimate. This represents a 35.14% decrease in earnings and a 22.53% decrease in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 12:02 pm

JAMF

Analysts have diverse opinions on Jamf Holding (NASDAQ:JAMF), with recent ratings ranging from bullish to bearish. Over the last three months, 10 analysts provided evaluations, showing a shift towards more bullish ratings in the last 30 days. The 12-month price target for JAMF has increased to an average of $22.3, reflecting an 8.25% rise from the previous target of $20.60. Jamf Holding, a leader in Apple Enterprise Management, has shown solid revenue growth of 15.59% as of December 31, 2023, but faces challenges with a net margin of -11.56% and an ROA of -1.11%. Despite these challenges, its ROE of -2.46% surpasses industry standards, and it maintains a low debt-to-equity ratio of 0.51.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 12:01 pm

MIRM

Analyst ratings for Mirum Pharmaceuticals (NASDAQ:MIRM) show a mix of bullish and somewhat bullish perspectives with no bearish views in the last three months. The average 12-month price target is $52.6, slightly down from $53.29. Mirum Pharmaceuticals, a biopharmaceutical company, has shown significant revenue growth and strong financial performance, with a focus on developing treatments for rare diseases. Analysts' actions range from maintaining to raising and lowering their price targets and ratings, reflecting their response to the company's performance and market conditions.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 12:01 pm

STKL

SunOpta's stock price increased following the announcement of stronger than anticipated Q1 sales and an upward revision of its FY24 revenue forecast.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:59 am

IPSC

Century Therapeutics reported Q1 2024 earnings with a GAAP EPS of $(0.45), surpassing the $(0.52) estimate, indicating a 13.46% beat and a 15.09% improvement from last year's $(0.53) per share. However, their sales of $855,000 fell short of the $1.262 million estimate by 32.25%, marking a significant 50.29% decline from the previous year's $1.720 million.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:58 am

X

Nippon Steel remains committed to its $14.9 billion acquisition of US Steel (NYSE:X) despite political and union challenges. The deal, facing bipartisan opposition and antitrust scrutiny in the US, is expected to close by late 2024. Nippon Steel has assured no job losses or plant shutdowns, with a $1.4 billion capital spending commitment and no layoffs through at least 2026.

Portfolio Pulse from Benzinga Neuro

May 09, 2024 | 11:57 am

FSLY

NET

RPD

SPT

TDC

The article highlights the top 5 oversold tech stocks with potential for significant gains, based on their low Relative Strength Index (RSI) values. These include Rapid7, Cloudflare, Sprout Social, Teradata Corporation, and Fastly, each experiencing recent price drops despite reporting various degrees of positive financial performance.

Portfolio Pulse from Avi Kapoor

May 09, 2024 | 11:57 am

VITL

Vital Farms' stock price increased following the announcement of Q1 sales results that exceeded expectations and the issuance of FY24 revenue guidance surpassing estimates.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:56 am

EMR

Emerson Electric Co (NYSE:EMR) reported Q2 FY24 results surpassing expectations with a 17% Y/Y net sales growth to $4.38 billion and adjusted EPS of $1.36. The company also declared a quarterly dividend of $0.525 per share. Following the results, Emerson revised its FY24 outlook positively and received mixed price target adjustments from Deutsche Bank, Baird, and Mizuho. Shares rose 4.9% to close at $112.65.

Portfolio Pulse from Avi Kapoor

May 09, 2024 | 11:56 am